June 10, 2021
The Kitasato Institute and Meiji Seika Pharma said on June 9 that they have begun joint R&D directed at “the discovery of ground-breaking COVID-19 therapeutics using next-generation derivatives of ivermectin and the development of infrastructure for antivirals.” The joint research...read more